C1-esterase inhibitor treatment in sepsis-Can we target the right patients?

Critical Care Medicine

Volumn 40, Issue 9, 2012, Pages 2735-2736

  Schlapbach, Luregn J ^a   Schibler, Andreas ^a   Jensenius, Jens C ^b  

^a MATER CHILDREN S HOSPITAL   (Australia)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; LECTIN;

INNATE IMMUNITY; LETTER; PATIENT SELECTION; PRIORITY JOURNAL; SEPSIS;

COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; MALE; SEPSIS;

EID: 84865469122     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318258eb7a     Document Type: Letter

References (5)

1. Igonin AA, Protsenko DN, Galstyan GM, et al: C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med 2012; 40:770-777
2. Hellemann D, Larsson A, Madsen HO, et al: Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum Mol Genet 2007; 16:3071-3080
3. Gulla KC, Gupta K, Krarup A, et al: Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010; 129:482-495
4. Sprong T, Mollnes TE, Neeleman C, et al: Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin Infect Dis 2009; 49:1380-1386
5. Agbeko RS, Fidler KJ, Allen ML, et al: Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children. Pediatr Crit Care Med 2010; 11:561-567